-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$10.33-19.11% Downside
Atara Biotherapeutics, Inc. Frequently Asked Questions
-
What analysts cover Atara Biotherapeutics, Inc.?
Atara Biotherapeutics, Inc. has been rated by research analysts at Stifel Nicolaus, Mizuho Securities, Goldman Sachs in the past 90 days.